I generally agree with Ohad most of the time. What I have tried to initiate or add in recent biotech down turns are those with revenue already or in near future, for example, MDVN, ITMN, FURX, ENTA, GILD. I also initiated positions in IMGN, XNPT - thought Ohad read my mind on both - which are under water, but I have no intention to add unless they go much lower. I generally focus on quality rather than cheap at the moment - obviously both would be the best - RARE about a week ago, PRTA, FMI today hit my buy order. I don't even care where they are going to be next week or next month. There are many attractive ones today than a few months ago for sure. Choose wisely!
Market Data 
Markets 
